Literature DB >> 17318967

Second primary tumors in mycosis fungoides patients: experience at the Northern Israel Oncology Center (1979-2002).

M E Stein1, Y Anacak, J Zaidan, K Drumea, E Gez, R Bar-Deroma, L Chetwer, A Kuten.   

Abstract

PURPOSE: Mycosis fungoides (MF) patients enjoy longstanding remissions following total skin electron irradiation (TSEI) but run the risk of developing secondary malignancies. Our purpose was to report our experience with the phenomenon of secondary malignancies in MF patients. PATIENTS AND METHODS: From 1979 to 2002, 84 patients with biopsy-proven MF were referred to our department for TSEI, using the modified Christie Hospital translational technique until 1992 and the Stanford technique after 1992. Median total dose was 32 Gy (range 16-44) Christie; 30 Gy (range 15-36) Stanford. Underdosed areas were boosted with a median total dose of 10-20 Gy.
RESULTS: During a median follow-up of 73 months (range 2-191) from the end of the TSEI, 12 (15%) patients developed 17 second primary tumors within the irradiated areas and 6 patients developed 7 second primary tumors, either simultaneously with the newly diagnosed MF or prior to introduction of radiation therapy.
CONCLUSION: The long-term prognosis was related solely to the second primary. Due to excellent long-lasting response rates following TSEI coupled with long-term survival, and the prognosis mainly associated to the stage and histology of the second malignancy, physicians should be aware of the possibility of second primary tumors.

Entities:  

Mesh:

Year:  2006        PMID: 17318967

Source DB:  PubMed          Journal:  J BUON        ISSN: 1107-0625            Impact factor:   2.533


  1 in total

Review 1.  Literature review of clinical results of total skin electron irradiation (TSEBT) of mycosis fungoides in adults.

Authors:  Fabio Ynoe de Moraes; Heloisa de Andrade Carvalho; Samir Abdallah Hanna; João Luis Fernandes da Silva; Gustavo Nader Marta
Journal:  Rep Pract Oncol Radiother       Date:  2013-09-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.